Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Correction to: Adv Ther 10.1007/s12325-022-02234-x

The authors regret to inform readers that the labels for the ‘treatment favour’ arrows were incorrectly labelled in Fig. 4. The ‘Favours UMEC/VI 62.5/25’ and ‘Favours comparator’ labels were appended to the wrong arrows and the corrected Fig. 4 is shown below. Please note that the data have not changed between versions.

Fig. 4.

Fixed effects model of mean difference in change from baseline in TDI focal score of UMEC/VI versus a dual therapy and b monotherapy at 24 weeks. Assessment of heterogeneity/inconsistency: I² = 0%; Q = 12.60; p = 0.4793. ACL aclidinium, CFB change from baseline, CI confidence interval, FOR formoterol fumarate, FP fluticasone propionate, GLY glycopyrronium, IND indacaterol, PBO placebo, SAL salmeterol, TDI Transitional Dyspnoea Index, TIO tiotropium, UMEC umeclidinium, VI vilanterol